Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
“We are committed to full profitability in ’19. We’ve proven in the past we can make profit very easily but we’re continuing to invest. For us it’s more of an input variable than an output variable.”
The pipeline isn’t a pipe dream any more, so say Exane analysts
Overall, Next 15 saw revenues grow 16% to £93.5mln in the six months ended 31 July (H1 2016: £80.5mln), while adjusted pre-tax profits rose by 13% to £12mln (H1 2016: £10.6mln)
“The "Nasstar 10-19" programme has gained significant traction in H1 and I am delighted that we have seen the results of the initiatives materialise in these positive results"
CEO Ray Barlow only joined the company earlier this year, but he’s already making his mark
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
"Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before”
The Collaborative Trajectory Analysis Project is essentially a place for drug developers to compare and contrast data to help them develop a useable drug
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now